Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 16/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GSR | P00390 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4308799 | 0.82 | MAPT (0.65) | TXNRD1MAPTS1PR4S1PR1MAPK1 | |
| SCHEMBL4305170 | 0.80 | TXNRD1 (0.56) | TXNRD1MAPTS1PR4S1PR1MAPK1 | |
| SCHEMBL4311846 | 0.80 | TXNRD1 (0.48) | TXNRD1MAPTS1PR4S1PR1MAPK1 | |
| SCHEMBL28489675 | 0.79 | TXNRD1 (0.57) | TXNRD1MAPTS1PR4S1PR1MAPK1 | |
| SCHEMBL9794246 | 0.78 | TXNRD1 (0.53) | TXNRD1MAPTS1PR4S1PR1MAPK1 | |
| SCHEMBL3408429 | 0.77 | TXNRD1 (0.47) | TXNRD1MAPTGSR | |
| SCHEMBL10654754 | 0.77 | TXNRD1 (0.55) | TXNRD1MAPTS1PR4S1PR1MAPK1 | |
| SCHEMBL5832677 | 0.77 | TXNRD1 (0.63) | TXNRD1MAPTRAB9AGSR | |
| SCHEMBL5832744 | 0.77 | TXNRD1 (0.46) | TXNRD1MAPTS1PR4S1PR1MAPK1 | |
| SCHEMBL9110118 | 0.76 | TXNRD1 (0.46) | TXNRD1MAPTS1PR4S1PR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2705039-B1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9422292-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20140135316-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| EP-2705039-A2 | BROMODOMAIN INHIBITORS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012151512-A2 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135316-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BRPF3, BRDT | TXNRD1 1156/4885MAPT 356/4885S1PR4 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.